Pancreatic REseCtion with level-III dissection versus versus standard pancreatic resection in patients with primary resected pancreatic head cancer – a single-center randomized controlled trial

Pancreatic REseCtion with level-III dissection versus versus standard pancreatic resection in patients with primary resected pancreatic head cancer – a single-center randomized controlled trial - Pan-Rec-3-TRIAL

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00032727

Enrollment

196

Registered

2023-11-06

Start date

2023-10-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25.0

Interventions

Group 1: Standard partial pancreatoduodenectomy Group 2: pancreatic head resection with level-III dissection via artery first approach

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Suspected primary resectable pancreatic head carcinoma. - Eligible for both surgical procedures Patients =18 years of age at the time of signing the informed consent form. - Presence of written informed consent from the patient prior to initiation of study-specific procedures - Patient's ability to give informed consent for study participation

Exclusion criteria

Exclusion criteria: - Borderline or locally advanced pancreatic cancer. - Evidence of distant metastases - Patient who is institutionalized due to a court or administrative order - Patient eligible for only one of the two procedures

Design outcomes

Primary

Measure	Time frame
Primary outcome measure is the rate of R0 resection (dorsal margin) defined according to the German S-III guideline Pancreatic Cancer.	—

Secondary

Measure	Time frame
Secondary outcome measures include: - Morbidity (Clavien-Dindo classification grade 0-5) - Comprehensive Complication Index - Blood loss (ml) - In-hospital mortality (surgery date/discharge date; yes/no) - 90-day mortality (death from any cause; yes/no) - postoperative hospitalization (surgery date/discharge date) - resected lymph nodes (number of lymph nodes) - anastomotic insufficiencies (yes/no) - pancreatic fistulas (yes/no) - lymph fistula (yes/no) - Overall survival (2 years) - disease free survival	—

Measure

Time frame

Secondary outcome measures include: - Morbidity (Clavien-Dindo classification grade 0-5) - Comprehensive Complication Index - Blood loss (ml) - In-hospital mortality (surgery date/discharge date; yes/no) - 90-day mortality (death from any cause; yes/no) - postoperative hospitalization (surgery date/discharge date) - resected lymph nodes (number of lymph nodes) - anastomotic insufficiencies (yes/no) - pancreatic fistulas (yes/no) - lymph fistula (yes/no) - Overall survival (2 years) - disease free survival

—

Countries

Germany

Contacts

Public ContactGeorg Wiltberger

Uniklinik RWTH Aachen, Klinik für Allgemein-, Viszeral- & Transplantationschirurgie

gwiltberger@ukaachen.de+49 241 80 38073

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026